Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
We enable cheaper, faster, and better genetic engineering of plants. We offer our ...
We enable cheaper, faster, and better genetic e...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology compa...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a...
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...
Gamida Cell is a clinical-stage biopharmaceutic...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Join the National Investor Network and get the latest information with your interests in mind.